Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705934 | 0.88 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| SCHEMBL4161455 | 0.87 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| Potassium Ion SCHEMBL11066423 | 0.85 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| SCHEMBL18366936 | 0.83 | SMN1; SMN2 (0.52) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| SCHEMBL1912587 | 0.82 | NPC1 (0.57) | RAB9ASMN1; SMN2NPC1L3MBTL1LMNA | |
| SCHEMBL25760467 | 0.81 | SMN1; SMN2 (0.51) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| SCHEMBL11075948 | 0.81 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL25759622 | 0.80 | ATM (0.67) | RAB9ASMN1; SMN2NPC1L3MBTL1ALDH1A1 | |
| SCHEMBL24131525 | 0.78 | LMNA (0.48) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 | |
| SCHEMBL4414649 | 0.74 | RAB9A (0.65) | RAB9ASMN1; SMN2NPC1L3MBTL1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-113801163-B | Organic arsenic-based II-type pyruvate kinase inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2025-03-04 | — | — | CN | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116640156-A | RIPK1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4215532-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215532-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023119210-A1 | NOVEL COMPOUND AS RIPK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| CN-102448928-B | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-102448928-A | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG | 2012-05-09 | — | — | CN | disclosed |
| EP-2435402-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | RIPK1, RIPK4, RIPK3 | RAB9A 3379/4885SMN1; SMN2 3889/4885NPC1 600/4885 |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | RAB9A 2855/4885SMN1; SMN2 456/4885NPC1 325/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | RAB9A 979/4885SMN1; SMN2 3272/4885NPC1 541/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | RAB9A 2855/4885SMN1; SMN2 456/4885NPC1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.